Over 75% of clinical trial sites who have not yet adopted eRegulatory plan to do so in 2019.

Why? In addition to growing industry pressure from sponsors who expect a digital site infrastructure, trial sites with eRegulatory platforms are introducing key advantages over those sites without eReg.

What are those advantages?